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Purpose: Rheumatoid arthritis (RA) patients appear to report a higher risk of chronic
obstructive pulmonary disease (COPD). While Chinese herbal medicine (CHMs) is proven
to lower COPD risk, the scientific evidence regarding its effect in relation to COPD onset
among them is limited. This longitudinal cohort study aimed to determine the relationship
between CHMs use and the COPD risk in RA patients.
Methods: Using the nationwide claim data, 8349 patients newly diagnosed with RA and
simultaneously free of COPD between 1998 and 2010 were eligible for enrollment. From this
sample, we enrolled 3360 CHMs users and 3360 non-CHMs users, randomly selected using
propensity scores matching from the remaining cases. They were followed until the end of
2012 to record COPD incidence. The hazard ratio (HR) of COPD with regard to CHMs use
was estimated by the Cox proportional hazards regression model.
Results: In the follow-up period, 136 CHMs users and 202 non-CHMs users developed
COPD, representing incidence rates of 5.16 and 7.66, respectively, per 1000 person-years.
CHMs use was associated with a 32% lower subsequent risk of COPD (adjusted HR: 0.68,
95% Confidence Interval: 0.54–0.84). Eight commonly prescribed CHMs were discovered to
be associated with lower COPD risk: Yan Hu Suo, Sānɡ Zhī, Dang Shen, Huang Qin, Jia-Wei
-Xiao-Yao-San, Shu-Jing-Huo-Xue-Tang, Du-Huo-Ji-Sheng-Tang and Ge-Gen-Tang.
Conclusion: A significant association of CHMs use with a lower risk of COPD onset in RA
patients was found, suggesting that CHMs could be integrated into conventional therapy to
reduce COPD risk.
Keywords: rheumatoid arthritis, Chinese herbal medicines, chronic obstructive pulmonary
disease, cohort study
Introduction
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disorder affecting
about 1% of the population worldwide, with many patients ultimately developing
progressive functional limitations and physical disabilities.1 Notably, it usually occurs
in middle-age adults, and more than one-third of affected individuals exhibit arthritis-
attributable work limitations, thus posing a significant burden for patients, families,
and social care systems.2 In the United States, a recent investigation revealed that the
healthcare cost of RA was approximately US$20,919 per affected person per year,
approximately three times higher than for non-RA patients.3 A review of the financial
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burden of RA in the US reported that the total annual costs
for RA was US$19.3 billion, and when adding the intangi-
ble costs, this amount exceeds US$39 billion.4
RA not only results in enormous economic losses but
also presents a significant problem for public health. Due
to the systemic inflammation inside the body, individuals
with RA have a higher risk of pulmonary disease, espe-
cially chronic obstructive pulmonary disease (COPD).
A recent British study following 24,625 patients with
RA, for over 10 years, found that those with RA had
a 47% higher risk of COPD than a non-RA patient
group.5 Another meta-analysis of four studies showed
that RA patients indeed had a greater risk of COPD than
did non-RA patients, with a pooled risk of 1.99 (95%
Confidence Interval [CI]: 1.61–2.45).6 Furthermore,
a study revealed that patients with RA, suffering from
concomitant COPD, had double the likelihood of mortality
of those with RA only.7 Accordingly, RA patients were
found to have 6–7 years’ lower life expectancy as com-
pared with the general population.8 These data, therefore,
imply that it is of utmost urgency to prevent or treat COPD
when managing RA subjects.
Recently, Chinese herbal medicines (CHMs) have been
widely used in clinical practice to treat patients with chronic
diseases. The estimated prevalence of CHMs usage varies
across populations, ranging from 16% to 90%.9–12 CHMs
facilitate improved clinical outcomes and promote improved
quality of life in individuals with chronic illnesses. A 10-year
cohort study of 729 patients with advanced breast cancer
showed that those receiving CHMs had a 45% reduced risk
of all-cause mortality than those who did not receive
CHMs.13 A randomized controlled trial of 352 individuals
with COPD compared the effectiveness of combining con-
ventional Western medicine with herbal products for 1 year.
The results suggested that the integration of CHMs and
Western medicine significantly improved pulmonary func-
tion, quality of life and psychological health (mood and
depression) in this population.14
Although CHMs have attracted attention for some time,
to the best of our knowledge, no study has been done to
verify its long-term effect among RA patients, let alone the
prevention of COPD in this group. From a standpoint of
disease management for RA, the identification of the asso-
ciation of CHMs with lower COPD risk may help improve
clinical outcomes and extend the life expectancy of RA
patients. We, therefore, analyzed a nationwide population-
based database to assess COPD risk among RA patients
who had either received or not received CHMs.
Methods
Data Source
For this study, we used a publicly released cohort dataset,
the Longitudinal Health Insurance Database (LHID), com-
prised of approximately 1,000,000 randomly sampled peo-
ple, and collected all records from 1996 to 2012. The
database has been confirmed by the National Health
Research Institute to be representative of the Taiwanese
population and its data have been used in many published
scientific papers.15 The encrypted information protects
patient privacy and allows linkage of all claims for the
same patient within the database. This database contains
all National Health Insurance (NHI) enrolment files, claims
data and the registry for prescription drugs, to provide
comprehensive utilization information on those individuals
covered by the insurance program. This study was con-
ducted in accordance with the Helsinki Declaration, and
was evaluated and approved by the local Institutional
Review Board and ethics committee of Buddhist Dalin
Tzu Chi Hospital, Taiwan (No. B10004021-3).
Study Subjects
Diagnoses in the insurance claims data were coded using the
International Classification of Disease, Ninth Revision,
Clinical Modification (ICD-9-CM). We identified the
patients who were aged 20 years or older and who sought
ambulatory health care services between 1998 and 2010 for
RA (ICD-9-CM code 714.0). To reduce the potential for
disease misclassification, only those with catastrophic illness
certification due to RA were recruited. In Taiwan, insured
persons with major diseases, such as schizophrenia, mood
disorders, immune disease and cancer, can apply for
a catastrophic illness certificate that grants exemption from
co-payment. The date when each RA patient gained
approval for catastrophic illness registration was considered
as the index date. To confirm that all patients with RAwere
indeed incident cases, only new-onset RA cases were
included (n=8725). Therefore, the 312 patients diagnosed
with COPD before the date of the first RA diagnosis were
excluded from the study. Patients were considered to have
a history of COPD if they had at least three outpatient visits
or at least one inpatient claim for COPD (ICD-9-CM codes
491, 492 and 496), dating from 1996, when the computer-
ized claims data from the LHID became available, until the
date of the cohort study. Also excluded were those with
missing data and those who were not followed for at least
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1 year after RA onset (n=64). Overall, we identified 8349
new-onset RA subjects (Figure 1).
Thereafter, we applied the frequency of visits to Chinese
medicine physicians to confirm the CHMs exposure of each
RA patient. Those who used CHMs for more than 30 days
after RA onset were considered CHMs users; enrollees trea-
ted for 30 days or less were considered non-CHMs users.16
Using this procedure, 3360 cases were designated as CHMs
users. A comparison cohort was randomly selected from the
remaining insured RA cases without CHMs use. For each RA
patient receiving CHMs treatment, one control patient not
receiving CHMs treatment was selected by 1:1 matching
based on a propensity score. Propensity scores representing
the likelihood of receiving CHMs were calculated using
logistic regression analysis, conditional on the baseline cov-
ariates listed in Table 1. Person-years (PYs) of the non-
CHMs users were determined by calculating the time from
the index date to the earliest of one of the following: the
diagnosis of COPD, the date of withdrawal from the insur-
ance program or the date of December 31, 2012. The PYs of
CHMs users was calculated from the initiation of CHMs in
combination corrected by immortal time bias.
8725 patients aged ≥20 years with newly diagnosed 
RA treated between 1998 and 2010
Subjects excluded:
i. Patients affected by COPD before the date of the 
first RA episode (n=312)
ii. Patients with missing data in the baseline 
characteristics and those followed-up for less than
one year (n=64)
4,698 were CHMs users 3,651 were non-CHMs
users
3,360 CHMs users were 
included for data 
analysis
3,360 non-CHMs users
were included for data 
analysis
Non-CHMs users were, each, matched with a CHMs-user cohort 
(for a 1:1 ratio) using propensity scores
136 patients were 
diagnosed with COPD
202 patients were 
diagnosed with COPD
Figure 1 Flowchart showing the method of selecting and following study subjects.
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Sociodemographic factors considered in this study included
age, sex, income for estimating insurance payment, and
urbanization level of the subject’s residential area.
Monthly incomes were stratified into three levels: ≤ New
Taiwan Dollar (NTD) $17,880, NTD$17,881–43,900 and ≥
NTD$ 43,901. Urbanization levels were divided into three
strata: urban (levels 1–2), suburban (levels 3–4) and rural
(levels 5–7) areas. Level 1 refers to the “most urbanized”
and level 7 refers to the “least urbanized” communities.17
Baseline comorbidities included hypertension (ICD-9-CM
codes 401–405), diabetes (ICD-9-CM code 250), heart dis-
ease (ICD-9-CM codes 410–429), chronic kidney disease
(ICD-9-CM code 585), cancer (ICD-9-CM codes 140–208),
alcohol dependence syndrome (ICD-9-CM code 303) and
tobacco use (ICD-9-CM code 305.1); all these data were
based on individual medical records 1 year prior to initial
entry into the cohort. In addition, medication usage was
stratified into whether or not the patient received corticos-
teroids or disease-modifying antirheumatic drugs for more
than 6 months after the index date.
Statistical Analysis
We performed χ2 test and t-test to examine the differences in
demographic characteristics and comorbidities between RA
patients with and without CHMs treatment. Then, the inci-
dence rate of COPD between the two groups was calculated
as the number of cases per 1000 PYs. Cox proportional
hazards regression analysis was then applied to compute
the HR with 95% CI of COPD risk in association with
CHMs use. To further test the robustness of the relationship
between CHMs use and COPD risk, we divided the CHMs
Table 1 Characteristics of the Study Subjects
Variables Total Group Non-CHMs Users CHMs Users P
N =3360 (%) N =3360 (%)
Age (years) 0.75
≤50 2743(40.8) 1378(41.0) 1365(40.6)
>50 3977(59.2) 1982(59.0) 1995(59.4)
Mean (SD) 53.8±14.0 53.80±14.3 53.72±13.5 0.81
Sex 0.53
Female 4945(73.6) 2461(73.2) 2484(73.9)
Male 1775(26.4) 899(26.8) 876(26.1)
Monthly income 0.44
Low 2972(44.2) 1504(44.8) 1468(43.7)
Median 3485(51.9) 1733(51.6) 1752(52.1)
High 263(3.9) 123(3.7) 140(4.2)
Residential area 0.84
Urban 3842(57.2) 1933(57.5) 1909(56.8)
Suburban 1043(15.5) 518(15.4) 525(15.6)
Rural 1835(27.3) 909(27.1) 926(27.6)
Medication use 0.50
Yes 5008(74.5) 2492(74.2) 2516(74.9)
No 1712(25.5) 868(25.8) 844(25.1)
Comorbidity
Hypertension 1816(27.0) 902(26.8) 914(27.2) 0.74
Diabetes 850(12.6) 411(12.2) 439(13.1) 0.30
Heart disease 1038(15.4) 499(14.9) 539(16.0) 0.18
Chronic kidney disease 87(1.3) 49(1.5) 38(1.1) 0.24
Cancer 206(3.1) 102(3.0) 104(3.1) 0.89
Alcohol dependence syndrome 14(0.2) 7(0.2) 7(0.2) 0.99
Tobacco use 7(0.1) 5(0.1) 2(0.1) 0.26
Follow-up time (years) (mean, median) 7.84(7.57) 7.85(7.56) 7.84(7.59)
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users into three subgroups: those who used CHMs for
31–365 days, those who used CHMs for 366–730 days and
those who used CHMs for more than 730 days. We also used
the Kaplan–Meier method to estimate the cumulative risk of
COPD between groups and tested the difference with the
log-rank test. Furthermore, a stratified analysis by age and
sex using Cox proportional hazards regression was con-
ducted to assess the HR of COPD among the subjects who
did and did not receive CHMs. Log(-log[survival]) versus
log of survival time plot was inspected to verify the propor-
tional hazards assumption. All analyses were conducted
using SAS version 9.3 software (SAS Institute Inc, Cary,
NC, USA). Differences of P < 0.05 were considered statis-
tically significant.
Results
The CHMs user and non-CHMs user cohorts provided data
for 3360 subjects each, with a mean duration of 7.85 and
7.84 years, respectively. After the matching procedure with
propensity score, there was no significant difference between
the two groups in age, sex, monthly income, residential area
and comorbidities, indicating that the two groups were com-
parable in terms of these characteristics (Table 1).
Among all eligible RA subjects, 338 first episodes of
COPD occurred, 202 in non-CHMs users and 136 in CHMs
users, during follow-up periods of 26,380.64 and 26,352.11
PYs, respectively. The incidence rate of COPD was signifi-
cantly lower in CHMs users than in non-CHMs users (5.16
vs 7.66, respectively, per 1000 PYs), with an adjusted HR
of 0.68 (95% CI: 0.54–0.84) (Table 2). Of note, those who
used CHMs for more than 730 days had reduced the risk of
COPD by 72%. Results of the Kaplan-Meier survival curve
and log-rank tests also supported a statistically significant
difference in the survival rate free from COPD across the
three groups of users during the follow-up period. Those
receiving CHMs for more than 730 days had a significantly
lower incidence rate of COPD than those not receiving
CHMs (P < 0.001) (Figure 2).
Table 3 presents the results from the analysis stratified
by age and sex. Collectively, a more significant beneficial
effect of CHMs was observed among older subjects.
Furthermore, multivariable stratified analysis verified that
the benefit of CHMs therapy in reducing the incidence of
COPD was more predominant in females, with an adjusted
HR of 0.57 (95% CI: 0.42–0.77) (Table 3). The 10 most
commonly prescribed herbal formulae for those with RA
are summarized in Table 4. Among them, the prescriptions
of Yan Hu Suo, Sānɡ Zhī, Dang Shen, Huang Qin, Jia-Wei
-Xiao-Yao-San, Shu-Jing-Huo-Xue-Tang, Du-Huo-Ji-
Sheng-Tang and Ge-Gen-Tang were associated with
a decreased risk of COPD (Table 4).
Discussion
This is the first evidence-based cohort study addressing the
association between CHMs use and COPD risk in patients
with RA using a large nationwide claims-based data
source. In this follow-up study of 15 years (1998–2012),
we found that patients with RAwho were receiving CHMs
had a 32% lower likelihood of COPD than those not using
CHMs. Furthermore, those receiving CHMs for more than
2 years were found to have a nearly 72% lower risk of
having COPD. The dose–response relationship may eluci-
date the causal relationships between CHMs use and the
decrease in the predisposition to develop COPD. No pre-
vious studies have been conducted to determine the long-
tern impact of CHMs use on COPD risk among RA
patients, thus rendering a comparison of results impossi-
ble. But the positive therapeutic effect of CHMs observed
in this study is consistent with earlier reports and adds to
the growing body of literature on this topic.12,18
Additionally, findings from our study indicated that
older patients benefited the most, by receiving CHMs
treatment, from lowering the risk of COPD, echoing the
findings of an earlier report.19 Previous research indicated
that younger adults are more likely than older adults to
gain prompt access to social resources and maintain close
Table 2 Risk of COPD for RA Patients with and Without CHMs Use
Patient Group N Events PYs Incidence Crude HR (95% CI) Adjusted HR* (95% CI)
Non-CHMs users 3360 202 26,380.64 7.66 1.00 1
CHMs users 3360 136 26,352.11 5.16 0.67 (0.54–0.83) 0.68 (0.54–0.84)
CHMs use for 31–365 days 2749 122 20,773.28 5.87 0.77 (0.60–0.94) 0.77 (0.60–0.93)
CHMs use for 366–730 days 346 9 2966.02 3.03 0.40 (0.20–0.77) 0.44 (0.23–0.80)
CHMs use for more than 730 days 265 5 2612.81 1.91 0.25 (0.11–0.63) 0.28 (0.11–0.67)
Notes: *Model adjusted for sex, age, urbanization level, monthly income, medication use and comorbidities.
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proximity to their social network.20 Younger RA patients,
therefore, might more easily adapt to the effects of the
progression of RA, thereby diluting the therapeutic effect
of CHMs. Furthermore, the reduction in risk of COPD was
found to be higher for females than for males (43% vs.
18%). We inferred that women might have superior health
consciousness than men and immediately sought medical
therapy at the slightest irregularity in well-being, and
therefore, may be more likely to comply with the pre-
scribed medical regimen to diminish the sequent risk of
COPD.21
An notable contribution of this work is the list of herb
products that are related to the reduced risk of COPD. First,
we observed the positive therapeutic effects of Yan Hu Suo
and Sānɡ Zhī in reducing the onset of COPD. These two
herbal products are typically used to relieve the level of
inflammation and neuropathic pain.22,23 A murine model
showed that the extract of Yan Hu Suo could suppress the
production of interleukin (IL)-6 and tumor necrosis factor-α
(TNF-α) by modulating the activation of nuclear factor-
kappa beta (NF-κB).24 These mediators are well known to
play an indispensable role in the pathogenesis of lung
Table 3 Incidence and COPD Risk for RA Patients with and Without CHMs Use, Stratified by Sex and Age
Variables Non- CHMs Users CHMs Users Crude HR (95% CI) Adjusted HR (95% CI)
Case PYs Incidence Case PY Incidence
Sex
Female 115 19,038.32 6.04 62 19,485.41 3.18 0.53 (0.38–0.71) 0.57Υ (0.42–0.77)
Male 87 7342.32 11.85 74 6866.71 10.78 0.91 (0.66–1.21) 0.82Υ (0.60–1.12)
Age (years)
≤50 27 11,230.89 2.40 20 11,182.57 1.79 0.74 (0.42–1.33) 0.74* (0.41–1.32)
>50 175 15,149.74 11.55 116 15,169.54 7.65 0.66 (0.52–0.83) 0.63* (0.50–0.80)
Notes: ΥModel adjusted for age, urbanization level, monthly income, medication use and comorbidities. *Model adjusted for sex, urbanization level, monthly income,
medication use and comorbidities.
Figure 2 Cumulative incidence of COPD in RA patients with and without receiving CHMs treatment during the 15-year study period (log-rank test, P< 0.001).
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diseases, especially COPD.25 Additionally, a recent in vivo
study revealed that Sānɡ Zhī inhibited the lipopolysacchar-
ide-induced production of the pro-inflammatory cytokine in
the Raw264.7 cell line by blocking the “BLT2 ligand-
BLT2”-linked autocrine inflammatory axis,23 which may
explain its therapeutic effect of decreasing the risk of
COPD onset.
Another herbal product proven effective in lessening
COPD risk among RA patients is Dang Shen. This remedy
belongs to the Campanulaceae family. The root extracts of
the Codonopsis species have been shown to possess antiox-
idant, anti-tumor, anti-microbial and immune-boosting
properties.26 A meta-analysis of 48 randomized controlled
trials highlighted that Dang Shen exerted a number of posi-
tive effects on pulmonary function, such as improvement of
forced expiratory volume (FEV1) and 6-min walking dis-
tance, compared with conventional pharmacotherapy.27Most
importantly, the integration of Codonopsis roots into routine
therapy was found to significantly enhance patients’ quality
of life compared to placebo, as measured by St. George’s
Respiratory Questionnaire (standard mean difference: −7.19,
95% CI: −10.82 to −3.56).27
Huang Qin also appears to modulate the immune
response, which may have important implications in chronic
inflammatory diseases such as COPD.18,26 Baicalin, a major
component of this formula, was proven in both in vitro and
in vivo studies to have anti-inflammatory, antioxidant and
antibacterial actions, as it has been shown to inhibit cytokines
and transcription factors. For example, using a rodent model,
Kim and colleagues discovered that Huang Qin suppressed
the activation of the MEK/ERK and IKKαβ/IκBα-dependent
pathways via c-Raf-1 activation, thereby altering the synth-
esis of inflammatory mediators.28
Among the commonly used multi-herb products for
RA patients, we noted that Jia-Wei-Xiao-Yao-San was
significantly related to a lower risk of COPD. Recent
scientific evidence indicates that this formula works by
increasing synaptic plasticity, upregulating the expression
of hippocampal brain-derived neurotrophic factor
(BDNF),29 and diminishing the level of inflammatory
markers,30 which in turn decreased the subsequent COPD
risk in RA patients. Elevated concentrations of both BDNF
and inflammatory cytokines in the sera are well documen-
ted before a definitive diagnosis of COPD,31 implying that
Table 4 Risk of COPD in Relation to the 10 Most Used Single-Herb and Multi-Herb CHMs Products for RA Patients
Chinese Herbal Product Number of Prescriptions Crude HR (95% CI) Adjusted HR* (95% CI)
Single-herb products
Yan Hu Suo 8699 0.45(0.34–0.62) 0.57(0.42–0.70)
Sānɡ Zhī 2119 0.41(0.24–0.70) 0.53(0.32–0.81)
Chuan-Niu-Xi 2186 0.67(0.43–1.04) 0.79(0.47–1.14)
Bei Mu 5221 0.61(0.54–0.96) 0.77(0.56–1.09)
Du-Zhong 5008 0.71(0.50–1.03) 0.72(0.51–1.08)
Dan-Shen 5775 0.52(0.36–0.75) 0.58(0.40–0.84)
Ji-Xue-Teng 4500 0.68(0.35–1.04) 0.69(0.37–1.04)
Huang Qin 5230 0.50(0.35–0.71) 0.59(0.45–0.90)
Hai Piao Xiao 3436 0.57(0.36–0.88) 0.77(0.47–1.15)
Da Huang 4585 0.53(0.35–0.81) 0.74(0.41–1.09)
Multi-herb products
Shu-Jing-Huo-Xue-Tang 9390 0.58(0.44–0.74) 0.64(0.50–0.83)
Jia-Wei-Xiao-Yao-San 8898 0.41(0.29–0.58) 0.65(0.46–0.90)
Shao-Yao-Gan-Cao-Tang 5722 0.72(0.55–0.94) 0.83(0.63–1.10)
Ge-Gen-Tang 5819 0.51(0.37–0.70) 0.65(0.47–0.89)
Dang-Gui-Nian-Tong-Tang 5033 0.63(0.45–0.88) 0.77(0.55–1.07)
Xue-Fu-Zhu-Yu-Tang 4463 0.68(0.50–0.94) 0.76(0.57–1.06)
Du-Huo-Ji-Sheng-Tang 6623 0.56(0.41–0.77) 0.57(0.42–0.77)
Chuan-Xiong-Cha-Tiao-San 4827 0.68(0.47–0.95) 0.73(0.44–1.10)
Zhi-Gan-Cao-Tang 3677 0.71(0.48–1.07) 0.77(0.52–1.12)
Gan-Lu-Yin 4101 0.68(0.41–0.94) 0.75(0.45–1.06)
Notes: *Model adjusted for age, sex, urbanization level, monthly income, medication use and comorbidities.
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these platelet mediators are likely involved in the patho-
genesis of COPD.
The positive therapeutic effects of Shu-Jing-Huo-Xue-
Tang and of Du-Huo-Ji-Sheng-Tang on the subsequent pre-
disposition to COPD were also identified in this study. Both
animal experiments and human studies have shown that the
anti-inflammatory property could be extracted from their
inherent compounds, such as ferulic acid and paeoniflorin
from Shu-Jing-Huo-Xue-Tang, and gentianine from Du-
Huo-Ji-Sheng-Tang. The relevant mechanisms by which
these ingredients exhibit their powerful anti-inflammatory
effects may be partially associated with inhibition of the
NF-κB signaling pathway,32–34 suggesting that these formu-
lae have the potential to treat airway inflammation diseases
in addition to rheumatologic disorders.
In our study, we also discovered that the prescription of
Ge-Gen-Tang was associated with lower vulnerability to
COPD, echoing a previous study finding.35 It was inferred
from this finding that this formula could ameliorate airway
remodeling by modulating airway inflammation and oxi-
dative stress in the lungs. Several recent studies have
shown that puerarin, a major isoflavone glycoside purified
from this formula, can not only help decrease the levels of
IL-4 and TNF-α but also reduce oxidative stress in
a rodent model of inflammatory disorders.35,36 A study
by Huang and colleagues further indicated that these
plasma inflammatory cytokines were related to measures
of the severity of airway diseases, such as the FEV1/forced
vital capacity ratio, and may be potential markers for the
evaluation of chronic inflammatory lung diseases.37
Findings from the current study have important clinical
and research implications. However, several limitations
should be noted when interpreting these results. First, cod-
ing errors are always a possibility in an administrative
database. To minimize this bias, we enrolled only subjects
with new-onset RA or COPD, and only after the patient had
at least three outpatient visits reporting consistent diagnoses
or at least one inpatient admission. To verify the accuracy of
medical records, the Taiwan NHI randomly samples claims
from hospitals, interviews patients and reviews medical
charts.15 Second, data on social network relationships, cop-
ing strategies and resources, religious beliefs or educational
levels were not available from the claims files, and con-
founding by any of these factors may exist. Future research
should include these uncontrolled variables to assess
whether the present findings can be replicated across
diverse groups of medical patients. Third, data regarding
RA severity were not available in this database, and failure
to adjust for this factor may bias the results. However, our
multivariate analysis considered the impact of multiple
comorbidities, including hypertension, stroke, diabetes,
heart disease, chronic kidney disease, cancer, alcohol
dependence syndrome and tobacco use. Furthermore, two
sensitivity analyses were also performed to further examine
the relationship between CHMs use and the subsequent risk
of COPD. The first sensitivity analysis, limited to RA
patients with no comorbidities, found CHMs to be still
protective against the development of COPD (adjusted HR
= 0.53, 95% CI, 0.38–0.73). Second, we used the prescrip-
tion of biological agents as a surrogate for RA severity,
dividing subjects by whether or not they received biological
agents for≧ 6 months after the index date. The proportion
of use of biological agents was 59.1% (1985/3360) in the
CHMs user cohort and 55.2% (1858/3360) in the non-
CHMs user cohort. The results of this re-analysis, that
took into account the use of biological agents, were essen-
tially the same as those reported in the original analysis
(adjusted HR: 0.59, 95% CI: 0.37–0.80). Findings from
these sensitivity analyses suggest that the severity of RA
did not appreciably impact the relationship reported herein.
Fourth, evidence from any observational cohort study is
generally less robust than that obtained from randomized
trials, because cohort study designs provide little safety
against existing confounding bias. Despite our meticulous
efforts to control for confounding factors, unpredictable
biases may remain from unmeasured or unknown confoun-
ders. Fifth, although our study revealed a substantial benefit
effect of CHMs use on the reduction of COPD onset among
RA patients, it must be recognized that these patients were
not randomly categorized into users and nonusers.
Therefore, caution should be exerted when interpreting the
findings. A randomized controlled trial is, therefore, recom-
mended to clearly determine the efficacy of these CHMs, as
well as the mechanisms that underlie their successful appli-
cation. These limitations notwithstanding, this study also
possessed several strengths. These include the immediate
availability of data, the comprehensiveness of the database
and the statistical power from the use of a large, nationally
representative sample. In addition, this retrospective 15-year
cohort study allowed us to robustly determine the relation-
ship between CHMs use and COPD in RA patients.
Furthermore, the present findings may serve as a useful
reference for future studies on this topic among other popu-
lations of patients with severe and chronic illnesses.
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Conclusion
This is the first large-scale nationwide cohort study to
show the association of CHMs use with the subsequent
risk of COPD among RA patients, thus suggesting a venue
for further studies of the effect of CHMs on other medical
conditions. We found that the integration of CHMs into the
RA treatment regimen reduced the subsequent risk of
COPD by 32%. Results of this study may serve as
a reference to help healthcare providers when planning
and implementing therapeutic interventions that seek to
improve the health of patients with RA.
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